Neurotech Industry 2016-2017 Report
More than 500 profiles of public and private neurotech companies including drugs, devices and diagnostics
Pipelines and market analysis for 20 brain and nervous system illnesses including: addiction, Alzheimer's disease, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia, stroke, and traumatic brain injury
Top neurotech investors, venture capital firms, and venture capital trends
Neurotech IPOs, M&A, Partnering and Licensing deals and public neurotech stock performance
Analysis of biological basis, current treatment options, and emerging therapeutic strategies
Analysis of compounds, cell therapies and devices in clinical trials (and abandoned) by company, mechanism of action and stage of development for each indication
Global and US market size, worldwide revenues for each indication
Extensive discussion of specific technological, demographic, regulatory and intellectual property trends
Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets.
Now in its 12th year, The Neurotechnology Industry 2016-2017 Report is an expanded and updated 650 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.
The report includes detailed information on products in development globally for over 20 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, traumatic brain injury and stroke.
- 1: Executive Summary
- The Brain Industry Revealed
- Neuropharmaceuticals
- Cell Therapies
- Neurodevices
- Neurodiagnostics
- Investment Risks and Opportunities
- Translating Neuroscience into Neurotech
- The Neurotech Market Opportunity
- Key Industry Facts and Findings
- 2: Trends and Drivers
- Converging Technology Drivers
- Crossing the Blood Brain Barrier
- Demographic Drivers
- More People Living Longer
- Social Drivers
- The Lifestyle Improvement Market
- Economic Drivers
- Global Economic Burden of Brain-Related Illness
- Rising Health Care Costs
- Research Funding
- US Government Research Funding
- Stem Cell Funding
- International Government Research Funding
- Foundations Focus on the Brain
- Intellectual Property Trends
- Global Intellectual Property Protection
- Patent Expirations
- Neurotech Merger and Acquisition Activity (2005-Q2,2016)
- 3: Neuropharmaceutical Sector
- Neuropharmaceutical Sector Overview
- Trends in Neuropharmaceuticals
- Neuropharmaceutical Partnering and Licensing
- Partnering and Licensing Personnel
- Partnering and Licensing Deals 2004-Q2,2016
- Neurology Markets and Pipelines
- Alzheimer’s Disease (AD)
- AAMI and MCI
- ALS
- Epilepsy and Seizure Disorders
- Huntington's disease
- Migraine
- Multiple Sclerosis
- Parkinson’s Disease
- Sleep Disorders
- Restless Legs Syndrome
- Stroke
- Traumatic Brain Injury
- Psychiatry Markets and Pipelines
- Addiction
- Anxiety Disorders
- Attention Disorders
- Depressive Disorders
- Bipolar Disorder
- Obesity
- Schizophrenia
- Cognitive Impairment Associated with Schizophrenia
- Sensory Markets and Pipelines
- Pain
- Retinal Disorders
- 4: Stem Cells and Neuroregeneration
- Defining Stem Cell Markets and Players
- Therapeutics
- Drug Discovery Tools
- Stem Cell Banking
- Stem Cell Approaches
- Background
- The Science of Transplantion
- Controlling Immune Rejection and Infection
- Sources and Harvesting of Stem Cells
- Embronic Stem Cells
- Fetal Stem Cells
- Adult Stem Cells
- Stimulation of Endogenous Stem Cells
- Stem Cells Scientific Hurdles
- Markets and Treatments in Development
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Hearing Loss
- Huntington’s Disease (HD)
- Multiple Sclerosis (MS)
- Parkinson’s Disease
- Retinal Disorders
- Spinal Cord Injury (SCI)
- Stroke
- Other CNS Diseases
- 5: Neurodevice Sector
- Neurodevice Sector Overview
- Neurodevice Markets
- Regulatory Process in the US
- Regulatory Process in the EU
- Neurodevice Sector Trends
- Investment by Major Device companies
- Neurodevice M&A Activity (2005-Q2, 2016)
- Neuroprosthetic Devices
- Cochlear Implants
- Retinal Implants
- Motor Prostheses and Brain Computer Interfaces
- Neuromodulation Devices
- Neuromodulation Device Clinial Trials and Recent Approvals
- Deep Brain Stimulation
- Essential Tremor
- Parkinson’s Disease
- Primary Dystonia
- Severe Obsessive Compulsive Disorder
- Treatment-Resistant Depression
- Epilepsy
- Traumatic Brain Injury and Stroke
- Transcranial Magnetic Stimulation (TMS)
- Alzheimer's
- Treatment Resistant Depression
- Migraine
- Transcranial Electrical Stimulation (TES)
- Transcranial Direct Current Stimulation (tDCS)
- Transcranial Alternating Current Stimulation (tACS)
- Transcranial Random Noise Stimulation (tRNS)
- Focused Ultrasonic Modulation
- Spinal Cord Stimulation (SCS)
- Chronic and Neuropathic Pain
- Spinal Cord Injury
- Vagus Nerve Stimulation (VNS)
- Epilepsy
- Treatment-Resistant Depression
- Obesity
- Peripheral Stimulation
- Assisted Breathing
- Epilepsy
- Fecal Incontinence
- Foot Drop
- Hypertension
- Migraine
- Neuropathic Pain
- Restless Legs Syndrome
- Sleep Apnea
- Stroke
- Urinary Conditions
- Gastric Modulation and Obesity
- Neurosurgical devices
- Radiosurgical Devices
- Neurosurgical Navigation and Equipment
- Image Guided Navigation (IGN)
- Intraoperative Magnetic Resonance Imaging (iMRI)
- Automated Surgical Systems
- Brain Monitoring
- Temperature Control Systems
- Neurovascular Intervention
- Ischemic Stroke
- Catheters, Stents and Perfusion devices
- Retrieval and Protection devices
- Ultrasound Thrombolysis
- Hemorrhagic Stroke
- Coils
- Liquid Embolics
- Stents
- Neurosoftware
- Attention Deficit Disorder
- Cognition and Aging
- Stress and Emotional Wellbeing
- Autism
- Addiction and Obesity
- Pain
- Schizophrenia
- Therapeutic NeuroGaming
- 6: Neurodiagnostics Sector
- Neurodiagnostic Sector Overview
- FDA Approval and Reimbursement of Diagnostics
- Neuroimaging Technologies
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging (PET, SPECT)
- Electro-encephalography (EEG)
- Magneto-encephalography (MEG)
- In Vitro Diagnostics
- In Vitro Diagnostics Regulatory Landscape
- Emerging Diagnostics for Alzheimer’s Disease
- Emerging Diagnostics for TBI
- Genetic Testing and Pharmacogenomics
- Protein Biomarker Assays
- Pattern Recognition in Diagnostics
- Emerging Diagnostics for Psychiatry
- Emerging Diagnostics for Autism
- Neuroinformatics
- Diagnostic Software
- 7: Private Neurotechnology Investment
- Private Investment in Neurotechnology
- Venture Capital Investment Trends
- Neurotech Venture Capital Investment
- Investing in Neuropharmaceuticals
- Investing in Stem Cells and Neuroregeneration
- Investing in Neurodevices
- Investing in Neurodiagnostics
- Private Company Financings, 2015
- Top financings 2004-2015
- Leading Neurotech Investors
- Leading Venture Capital Firms
- 8: Public Neurotechnology Investment
- Investing in Public Neurotech Companies
- Neurotech Stock Universe
- Neurotech Initial Public Offerings
- NeuroInsights Neurotech Index
- 9: Neurotechnology Research Centers
- Leading Neurotechnology Research Centers
- University of California, San Francisco (UCSF)
- University of California, Los Angeles (UCLA)
- University of California, San Diego (UCSD)
- Harvard
- Stanford University
- Massachusetts Institute of Technology (MIT)
- Columbia University
- Washington University, St. Louis
- University College London (UCL)
- Karolinska Institutet, Stockholm
- RIKEN Brain Science Institute, Japan
- Places to Watch
- National Brain Research Centre (NBRC), India
- Neurosciences Victoria, Australia (NSV)
- Univeristy of Helsinki, Finland
- 10: Leading Neurotechnology Regions
- The Global Neurotech Economy
- Nexus Ranking and Methodology
- Established Neurotech Nexus
- Emerging Neurotech Nexus
- Nascent Neurotech Nexus
- Conclusions and Policy Recommendations
- 11: Company Profiles
- Neuropharmaceutical & Cell Therapy Companies: Private
- Neuropharmaceutical & Cell Therapy Companies: Public
- Neurodevice Companies: Private
- Neurodevice Companies: Public
- Neurodiagnostic Companies: Private
- Neurodiagnostic Companies: Public
- 12: Index
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
